Moderna Therapeutics saw “positive” results from early vaccine tests. Photo: Aflo/Shutterstock . Moderna, the Boston-based biotech firm that began testing the vaccine in March, announced that eight healthy patients, who each received two doses of the vaccine, developed antibodies that fight the virus.
In Moderna’s Phase 1 trial, half of the eight patients received two doses of 25 micrograms, and the other half received two doses of 100 micrograms. Those who received the smaller does showed levels of antibodies similar to those in people who have recovered from COVID-19. For those who received the higher dose, antibody levels “significantly exceeded” those in recovered patients.
In an interview with Stat News, Zaks said there is a balance to strike between an effective dosage level and using as little vaccine as needed, allowing for maximum production. “The sense is, at the end of the day, we’re going to narrow it down on somewhere between 25 and 100,” he said. “It’s going to be really hard math for us.”
🙏